Skip to content
Annika Bansal – Lifestyle
Author:
Io Therapeutics, Inc.
RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models
August 5, 2026
Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.
March 25, 2026